ABSTRACT: Primordial germ cells (PGCs) have long been considered the link between one generation and the next. PGC specification begins in the early embryo as a result of a highly orchestrated combination of transcriptional and epigenetic mechanisms. Understanding the molecular events that lead to proper PGC development will facilitate the development of new treatments for human infertility as well as species conservation. This article describes the latest, most relevant findings about the mechanisms of PGC formation, emphasizing human PGC. It also discusses our own laboratory's progress in using transdifferentiation protocols to derive human PGCs (hPGCs). Our preliminary results arose from our pursuit of a sequential hPGC induction strategy that starts with the repression of lineage-specific factors in the somatic cell, followed by the reactivation of germ cell-related genes using specific master regulators, which can indeed reactivate germ cell-specific genes in somatic cells. While it is still premature to assume that fully functional human gametes can be obtained in a dish, our results, together with those recently published by others, provide strong evidence that generating their precursors, PGCs, is within reach.
Introduction
Induced pluripotency, a biological discovery that has revolutionized science and biomedicine, was informed by the fact that key pluripotency-/oocyte-related factors can reprogram a somatic nucleus to an embryo-like pluripotent stage (Wilmut et al., 1997; Takahashi et al., 2007) . The same approach should make it possible to generate primordial germ cells (PGCs) from somatic cells by identifying the factors involved in the differentiation process during in vivo germ cell development.
PGCs, the progenitors of gametes, provide the link between one generation and the next. By transmitting the genome, gametes constitute the primary means to achieve biological descendants. Defects in gamete formation could compromise species conservation. In humans, there are approximately 70 million couples worldwide unable to have a child of their own. Granted, the causes of human infertility are not always due to a defective egg or sperm, however having a reliable method to produce functional gametes will go a long way towards alleviating this burden.
PGC specification begins early in the embryo and results from a highly orchestrated combination of transcriptional and epigenetic mechanisms, including the erasure of imprinted genes, while keeping the genome information intact.
The study of PGC specification has been hindered by the small number of cells-20 to 40-in the initial population of PGCs and our inability to expand them in vitro. PGCs have also proven difficult to track in the developing embryo. Moreover, the fact that most of the PGC markers can be found in other cells has, until recently, made it harder to trace embryonic PGCs; for example, the PGC marker tissue-nonspecific alkaline phosphatase (TNAP) also shows up in other cell types, including pluripotent cells (O'Connor et al., 2008) .
Nonetheless, we have made progress towards the identification and characterization of PGCs in mice and humans. PRDM14 has emerged as a specific PGC marker in mice, and the cellsurface markers KIT (Gkountela et al., 2015; Guo et al., 2015) and CD38 , alone or in combination with TNAP , have been used to isolate human PGCs (hPGCs). Highthroughput single-cell gene expression and genome-wide bisulfate sequencing (GWBS), together with potent bioinformatic tools, have open the possibility of studying such rare and transient cell types as PGCs (Smallwood et al., 2014; Taher et al., 2015) .
Much of our current knowledge about PGCs derives from mouse studies, establishing the role of Blimp1 (Prdm1), Prdm14 and Tfap2c genes in mouse PGC (mPGC) formation and gametogenesis Hayashi et al., 2011; Saitou et al., 2012) . A number of different experimental strategies, such as supplementation of cytokines (Hayashi et al., 2011; Hayashi et al., 2012) , overexpression of transcription factors (Nakaki et al., 2013) , or inhibition of ERK signaling (Kimura et al., 2014) , have been used to differentiate in vitro mouse embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into PGC-like cells, mainly through an intermediate state of epiblast-like cells. Researchers have also shown that these in vitro-derived germ cells contribute to spermatogenesis (Hayashi et al., 2011; Nakaki et al., 2013) and oogenesis (Hayashi et al., 2012) , and while they display some morphological defects-such as fragile and misshapen oocytes-they can reach fertilization and full-term development (Hayashi et al., 2011 (Hayashi et al., , 2012 Nakaki et al., 2013) . Quite possibly, the successes obtained so far towards the generation of mouse gametes from pluripotent cells in vitro result from efforts made over the last decade to understand the early stages of PGC reprogramming in vivo (including Surani et al. and Saitou et al., among others) . Similar studies in humans are impossible to perform in vivo, but conversely, the in vitro differentiation of the early stages of human PGCs using ESCs (Kee et al., 2009) or iPSCs (Panula et al., 2011 ) is possible, even from patients with such reproductive deficiencies as primary ovarian insufficiency (Leng et al., 2015) or azoospermia (Ramathal et al., 2014) . The literature reveals a stream of reports about new and more efficient differentiation protocols (Sasaki et al., 2015) .
Transdifferentiation, defined as the direct conversion of one particular cell type into another without going through an intermediate transient state of pluripotency, represents another valid strategy for obtaining a desired cell type. This approach has been proven feasible for multiple types of cell; under in vitro conditions, numerous examples have been reported. Most reports describe the forced expression of tissue-specific transcription factors and microRNAs, but, in some instances, small molecules have proven sufficient to elicit such cellular reprogramming feats . As such, it may offer an alternative source of cells, primarily for cardiac, hepatic and neural regeneration (Lin et al., 2013; Zhang et al., 2016) . Transdifferentiation has also been proposed as an alternative for generating germ cells, and some preliminary attempts look encouraging (Table I) . Our group is also exploring the effects of overexpressing germ cell-related factors to induce the transdifferentiation of somatic cells into germ cell precursors using specific culture conditions that can partially recreate the testicular environment. This article will summarize the results we have obtained so far.
We still lack an accurate description of the main specific factors involved in hPGC specification. We are far from understanding the molecular processes involved in epigenetic resetting of human germ cells and their progression through meiosis. Addressing these challenges requires a detailed analysis of the transcriptome and epigenome of the hPGC at multiple stages of development. Only by meticulously recapitulating the natural process, as demonstrated by Saitou's group for mice (Hayashi et al., 2011; Sasaki et al., 2015) , will we likely accomplish the differentiation of human germ cell precursors in vitro. The alternative, i.e. simply flooding cells with signaling molecules and factors, will yield very little progress. 
In vivo human PGC specification

Male
In vivo (Rat) Recovery of fertility after injection of adipose-tissue-derived mesenchymal stem cells Cakici et al. (2013) In vitro/in vivo (Rat) Potential spermatogenesis recovery with bone marrow mesenchymal stem cells in an azoospermic rat model Zhang et al. ( 2014) (Chicken) Bone marrow-cell-mediated production of transgenic chickens. Heo et al. ( 2011) In vitro (Mouse) Retinoic acid induced myoblast transdifferentiation into premeiotic Stra8-positive cells. 
Male germ cells from fetal bone marrow stem cells Hua et al. (2009) 
Female
In vitro
Amniotic fluidstem cells differentiated into primordial follicle oocytes Yu et al. (2014) Amniotic stem cells differentiated into artificial oocytes Cheng et al. (2012) Umbilical cordmesenchymal stem cells differentiated into oocyte-like cells Qiu et al. (2013) Hepatic cell line differentiated in vitro into artificial oocytes, some of which spontaneously activated and developed germ cell/embryonic tumors in vivo Ma et al. (2013) Germ cell-like phenotype from mesodermal cells (foreskin fibroblast and bone marrow mesenchymal cells) Medrano et al. (2016) involved in hPGC formation (Gkountela et al., 2015; Guo et al., 2015; Sasaki et al., 2015; Tang et al., 2015; Medrano et al., 2016) . We now know that hPGCs differentiated in vitro (also called hPGC-like cells) are similar to those isolated in vivo and resemble the seminoma cell line Tcam2 . Have we reached the tipping point regarding the basic molecular knowledge needed to start devising evidence-based transdifferentiation protocols for hPGCs and gametes?
Transcriptome profiles in human versus mouse PGCs
The specification of hPGC begins at approximately E12 to 16 (Weeks 2-3) and continues for several weeks. Week 9 is considered a critical time point in the development of human fetuses; it marks the divide between early and late hPGCs. It also marks an important milestone: the asynchronous entry of female hPGCs into meiosis and the quiescent mitosis of male cells that will undergo meiosis after puberty (Leitch et al., 2013; Tang et al., 2015) . Recent transcriptome analyses have shown that, during the early stages of development, hPGCs are more homogenous, closely resembling pluripotent inner cell mass (ICM) cells . Nonetheless, they cluster as a single group, unlike ICM cells, and they are specifically enriched for genes involved in the base excision repair (BER) pathway, like mPGCs (Gkountela et al., 2015; Guo et al., 2015) . This suggests that BER could be involved in global DNA demethylation during hPGC specification, in contrast to the mechanism for the erasure of DNA methylation that affects the zygote just after fertilization; this erasure relies on a global, asymmetric demethylation of parental genomes caused by the absence of DNA methylation maintenance and by demethylation through hydroximenthylation, followed by lineage-specific reacquisition of methylation. Human and mouse PGCs share the expression of key germ cell genes (e.g. BLIMP1, TFAP2C, UTF1, DAZL and DDX4), as well as pluripotency genes (e.g. OCT4, NANOG, PRDM14 and LIN28A), but some differences exist: (i) key pluripotency factors strongly expressed in mouse PGCs are absent in hPGCs and hPGC-like cells (hPGCLCs) differentiated in vitro (e.g. ESRRB, SOX2, SOX3 and ZIC3); and (ii) some factors downregulated in mPGCs are highly expressed in hPGCs (KLF4 and TFCP2L1, also detected in the ICM; SOX17 and GATA4, two endoderm specifiers; and TEAD4, a trophectoderm specifier) . In addition, the gene regulatory network of hPGCs shows that SOX17 acts as a master regulator of human germ cell fate, while it is dispensable in mPGCs (Magnusdottir et al., 2013; Nakaki et al., 2013; Irie et al., 2015) . SOX17 is upstream of BLIMP1, a gene known to repress mesendoderm differentiation and to play a similar role in mouse and human PGCLCs. In contrast, research has shown PRDM14, a key factor in mPGCs that is involved in the suppression of DNA methylation, to be dispensable for hPGC development (Sugawa et al., 2015) . PRDM14 is upregulated later in hPGCs than in mPGCs, and it is downstream of BLIMP1 .
Some studies have reported differences in the temporal gene expression of hPGCs, as summarized in Table II . These differences include SOX17, a master regulator of hPGCs , whose expression has been reported from early to later stages of hPGCs as well as in migrating and gonadal PGCs (Gkountela et al., 2015; Guo et al., 2015; Tang et al., 2015) . These apparent discrepancies could be attributed to subtle differences in the isolation of hPGCs, to the timing of fetus retrieval, or to biological heterogeneity in hPGCs due to differences among embryos. Nonetheless, these studies provide new information about specific human germ cell factors that could help in the identification, isolation, characterization, or induced differentiation of this special cell type.
DNA methylation changes during PGC specification
The epigenetic reprogramming of PGC implies the erasure of DNA methylation, including genomic imprints and repetitive elements, although some methylated loci persist. The reasons for the erasure of most epigenetic information in germ cells remain unknown, but it could provide a mechanism to prevent the transmission of acquired epimutations during life. The methylome of human and mouse PGCs shows similar dynamics during initial demethylation (from E10.5 to Week 5.5); later, male mouse PGCs remain demethylated for a short time (a few days), unlike male hPGCs, which remain demethylated for several weeks, remethylating only in the second trimester of pregnancy (Leitch et al., 2013) . Human PGCs reset their methylome by repressing maintenance and de novo DNA methylation pathways while activating Ten-eleven Translocation (TET)-mediated hydroxymethylation . Molecular features compatible with the resetting of DNA methylation in nascent hPGCs have been confirmed by immunofluorescence and bisulfate sequencing (BS-seq). By Week 4, regardless of the sex of the fetus, migratory hPGCs already exhibit lower global 5-methylcytosine 5mC than somatic cells, and this remains low until Week 9 .
Researchers considering the effect of sex, found clear differences between female and male hPGCs. Female hPGCs at Week 5.5 display global hypomethylation (16% of CpG methylation versus 79% in H9 ES cells and somatic cells), which continues to decrease until Week 7 (4.5% of CpG methylation) and still remains low at Week 9 . Two other studies confirmed this tendency by investigating hPGCs isolated in vivo, although with slightly different methylation levels and timelines. Guo et al. (2015) reported similar results with Week 7 male PGCs, which already exhibited decreased methylation (19.4% compared to more than 80% in 5-week-old embryos), and the gradual loss continued until Weeks 10-11 (6-8% methylation). Clark's group reported a more moderate decrease of methylation in male hPGCs (30.7% of CpG methylation at Week 8 versus 40% in ICM) (Gkountela et al., 2015) . This study also showed that the decrease of methylation starts at Week 5.5 and in female PGCs continues until Week 16, when it becomes more profound (16.7% CpG methylation).
With regards to DNA remethylation, Guo and colleagues reported its onset in female PGCs at around Week 11, whereas its onset in male PGCs takes place after Week 19 . Gkountela et al. found that the male genome initiates de novo methylation between Weeks 8.5 and 19.5 of development (Gkountela et al., 2015) . In general, these global results demonstrate that human preimplantation embryos exhibit significantly more demethylation (approximately 40% methylation at ICM) than gametes, but less than PGCs, which undergo a still more dramatic resetting of DNA methylation (Gkountela et al., 2015; Guo et al., 2015) . In hPGCs, erasure of DNA demethylation includes all genetic features (CpGi, exons, introns, intergenic regions and enhancers) regardless of CpG density, although demethylation at gene bodies takes places slightly later (around Week 9). Nevertheless, despite the overlapping mechanisms participating in DNA demethylation, some repetitive sequences retain intermediate methylation. In addition, a cluster of repeat-free tiles also retain partial methylation, showing that, for some as yet undetermined reasons, some genomic regions do escape global demethylation . It is speculated that any such regions that are spared from resetting their epigenetic landscape, may be involved in transgenerational epigenetic inheritance.
Gkountela et al. uncovered variations in DNA methylation levels between early and late hPGC stages, demonstrating that 3255 differentially methylated regions (DMRs; 94.5%) lose methylation and 190 DMRs (5.5%) gain methylation in late hPGCs relative to early hPGCs (Gkountela et al., 2015) . Further, this study confirmed that the mouse germline also gains in 5mC and that this takes place in the same intragenic regions (exons, splice sites, promoters and 3′UTRs) as in hPGCs (Gkountela et al., 2015) . This finding illustrates that although de novo DNA machinery is considered disabled during this period, some residual DNA methylation activity still persists.
Gene imprinting and PGC development
Imprinted regions also undergo demethylation during PGC specification but not during reprogramming of the preimplantation embryo. In the mouse, most of the imprinting control regions (ICRs) retain partial methylation (20-50%) at E10.5 (Hackett et al., 2013; Kobayashi et al., 2013) . In contrast, in humans, only 6 of 22 ICRs have methylation higher than 20% at Week 5, and from Weeks 7-10, all ICRs are demethylated, with the exception of IGFR2 and PEG10 ICRs, which seem to escape full demethylation. Hypomethylation of ICRs persists until Week 19 Tang et al., 2015) . Gkountela and colleagues (Gkountela et al., 2015) confirmed their previous data showing that, in late hPGCs, the paternally methylated imprinted genes H19 and MEG3 and the maternally methylated imprinted genes PEG3 and KCNQ1 become almost completely demethylated in the ICRs (Gkountela et al., 2013) . These results confirm that imprinting marks are deleted during PGC formation, the unique time interval when the methylation of these regions undergoes exceptional erasure. However, specific factors, such as IGFR2 and PEG10, seem to resist this resetting . While the relevance and mechanism involved in these demethylationresistant genes remain unknown, we expect that any strategy to generate hPGCs in vitro will need to recapitulate the imprinting reprogramming observed during in vivo development.
X chromosome reactivation in PGCs
Another characteristic feature of PGC reprogramming in female cells is X chromosome reactivation. The hypomethylation of the X chromosome CGi promoters lasts from Weeks 5.5 to 9 X chromosome CGi promoters are hypomethylated from Weeks 5.5 to 9, and the typical foci of H3K27me3 that mark the inactive X chromosome are absent at this stage but remain in the somatic cells of the gonads . In addition, the expression of the X chromosome's genes increase around 1.6-fold in female hPGCs starting at Week 4, when the HDHD1 (the X-linked ichthyosis gene) is expressed from both alleles .
5-Hydroxymethylcytosine (5hmC)
A hallmark of active demethylation through TET proteins is the presence of 5hmC, the first oxidative product of 5-methylcytosine.
The participation of TET enzymes in hPGC specification has been also proposed (Gkountela et al., 2013) . Immunofluorescence analysis shows the dynamic expression of 5hmC with several peaks and valleys during the early weeks of development. Some nuclear foci of 5hmC are present at Week 4 of development, but they become totally depleted by Week 9 . Between Weeks 7 and 11, hPGCs exhibited low levels of 5hmC, but TET-assisted bisulfate sequencing (TAB-seq) confirmed that male 10-week-old hPGCs contained 1.9% of 5hmC in their genome, which is low but significant. After that, 5hmC is lost in hPGCs in the testis from Weeks 13.5 to 16, but an enrichment of 5hmC is again detected at around 17 weeks, with the initiation of imprinting erasure. In female hPGCs, 5hmC is heterogeneous (enriched in some but not all) between Weeks 11 and 19 Gkountela et al., 2013) .
Genic regions show higher levels of 5hmC with slightly enriched gene bodies, whereas repetitive elements contain the lowest levels of 5hmC . Global depletion of 5mC occurs in hPGCs differentiated in vitro, and the presence of 5hmC is also detected in vivo at around Weeks 16-16.5 of hPGC development, when imprinting erasure is initiated (Gkountela et al., 2013) . Curiously, at around Days 4-5 of the hPGC-LCs, researchers also observed the partial erasure of 5mC and concomitant 5hmC enrichment at the H19 and GNAS genes' ICRs .
Evidence of a disabled DNA methylation pathway in HPGCs
During the hPGC demethylation period, researchers found that UHRF1-an essential cofactor of the methylation-maintaining DNA methyltransferase 1 (DNMT1)-and the de novo methyltransferases of the DNMT3A, DNMT3B and DNMT3L genes were all expressed at the mRNA level (Gkountela et al., 2015) ; however, protein expression was absent. This evidence points to a 'disabled' DNA methylation machinery at this stage in development. In contrast, they found protein expression of TET1 and TET2, although they did not observe oxidized derivatives of 5hmC (5fC and 5caC) or increased thymine DNA glycosylase-known to be involved in active 5mC demethylation (Gkountela et al., 2015; Tang et al., 2015) . Research suggests that BLIMP1 and SOX17 sustain the epigenetic program to 5mC erasure and continue to be expressed from Weeks 4 to 9. Furthermore, the loss of BLIMP1 in hPGC-LCs negatively affects the initiation of DNA demethylation, resulting in the higher expression of both DNA methylation pathways (de novo and maintenance) and the reduction of TET1 and TET2 .
Uncoupling DNA methylation and gene expression in hPGCs DNA methylation in gene promoters typically represses expression, whereas DNA methylation in gene bodies usually correlates positively with gene expression (Jones, 2012) . Considering that global hypomethylation is a feature of PGC reprogramming, this could result in a promiscuous global gene expression state. However, during hPGC formation, promoter demethylation and gene expression appear to be uncoupled . That is, most of the gene promoters (99.5%) are hypomethylated, but more than 80% of genes are not differentially expressed. However, specific factors related to the Piwiinteracting RNA (piRNA) metabolic process (e.g. MAEL, PIWIL1 and PIWIL2), related to sexual reproduction (e.g. NANOS3, DAZL and TEX11), or containing DEAD-like helicases (e.g. DDX4, DDX43 and DDX53) or Tudor domains (RNF17, TDRD5 and TDRD9), which show promoter demethylation, are upregulated . Some of these factors are required to control the activity of retrotransposons, which display demethylation in a higher fraction during this stage. An exacerbated expression of these repetitive elements could have dramatic consequences for the stability of the genome, as reported for spermatogenesis (Heyn et al., 2012) . Another group of genes that show upregulation and hypomethylation are the Krüppel-associated box zinc finger genes (KRAB-ZFPs). This group includes genes with transcriptional repressor activity, and they participate in imprint establishment, germ cell differentiation, and retrotransposon repression; thus, they could prove essential for PGC specification (Jacobs et al., 2014) . This reveals the involvement of other signals in the transcriptional regulation of PGCs, repressing the expression of hypomethylated genes while allowing the expression of specific factors required during PGC formation.
Histone modifications as regulators of gene expression in PGCs?
RNA-seq analysis has revealed that the enzymes responsible for H3K9me2 and H3K9me3 (EHMT2 and SETDB1, SUV39H1 and SUV39H2) are all expressed in PGCs. In contrast to mice, hPGCs are depleted of H3K9me2, but H3K9me3 shows a clear signal with striking punctuated dots at different stages (Gkountela et al., 2015) . Specifically, the detection of H3K9me3 at Weeks 9-11, when residual DNA methylation is minimal, suggests that this histone repressive mark could be the main heterochromatin factor repressing global gene expression during this period Tang et al., 2015) .
Retrotransposons and PGC development
DNA methylation of the promoter region is a central mechanism for controlling retrotransposon expression in PGCs (Bourc'his and Bestor, 2004). As previously mentioned, hPGCs undergo progressive demethylation between Weeks 5.5 and 9. Globally, transposons follow the same tendency; however, some repetitive elements (e.g. LINE-1 and SVA loci) remain partially methylated. One half of SVA loci show greater than 30% methylation during all stages of hPGC development . LINE-1 younger elements, which are more active in retrotransposition, tend to be more methylated than older elements. For example, L1 has higher levels of residual methylation (22-24%) than the evolutionarily older L2 (6-7%; Guo et al., 2015) . Also, DNA methylation is much higher in the transposon of young L1HS, as well as in L1PA2, L1PA3 (Gkountela et al., 2015) and L1PA; the youngest L1 subfamily shows the highest methylation (greater than 30%; Tang et al., 2015) . Despite these differences in the DNA methylation of specific transposon subclasses, the expression of all transposons remains low (FPKM of less than 1.0), with a tendency to decrease during the late stages of hPGC development (Gkountela et al., 2015) . In general terms, hPGCs show the expression of repetitive elements uncoupled with DNA methylation, with persistent repression in hypomethylated regions. Nonetheless, this methylation uncoupling in hPGCs has an important exception. SVA elements display a negative correlation between methylation and expression, and hypomethylated SVA loci are upregulated from Weeks 5 to 9 in hPGCs. However, SVA mobilization depends on L1HS, which codifies the RNA-binding chaperone ORF1, endonuclease and reverse transcriptase ORF1 (Hancks et al., 2012) . Fortunately, and perhaps as a result of evolution to avoid genetic chaos, L1HS remains repressed in hPGCs, probably by the PIWI-piRNA pathway (Pezic et al., 2014) , and L1HS limits the retrotransposition activity of SVA and other retrotransposons in the germline. Additional repressive epigenetic marks, such as H3K9me3, have been suggested as being responsible for repressing expression and preserving hPGC genome integrity independent of DNA methylation (Gkountela et al., 2015; Guo et al., 2015; Tang et al., 2015) .
Other repetitive elements, such as the alpha satellites (ALRs), maintain higher levels of methylation than retrotransposons at this stage (36.5%; Guo et al., 2015) . Humans and mice have a similar number of regions that escape demethylation, but they are not well conserved at the sequence level (only 3% of the conserved regions in humans show more than 10% of the methylation in the orthologous region in mice) . A detailed analysis of regions that escape DNA demethylation has revealed that a majority of annotated repeats have persistently methylated regions (with 30% of the average CpG methylation). However, 6% (7071) of these sequences were depleted of retrotransposons (less than 10% overlap with repeats), and 1.22% (1426) were free of repeats. Repeat-poor regions that escaped demethylation were located in intergenic regions, gene bodies, promoters, enhancers and CpGi. Functional analysis of these regions revealed their expression in the brain and participation in neural development; they are associated with diseases such as obesity-related traits, schizophrenia and multiple sclerosis . (Gkountela and colleagues 2015) also identified persistent methylation in 1471 regions (using a cutoff of 50% average CpG methylation in each 200 bp window) which correspond mainly to exons. Selecting the genes with persistent methylation at the gene body or ±5 kb from the TSS, uncovered 585 genes involved in such diverse functions as chromatin remodeling (SETDB1, SETD1A, UHRF1 and CHD6), cell adhesion (CDH4 and CDH12) and MAP kinase signaling (MAPK8 and MAPK10). Considering that hPGCs generally exhibit an evident uncoupling of methylation and transcription, this persistent methylation has more relevance for the possible role of these sequences in the transgenerational inheritance of epigenetic memory than in the regulation of gene expression. This escape from demethylation has also been reported in mPGCs (Seisenberger et al., 2012; Kobayashi et al., 2013) . Support for this hypothesis comes from the fact that most regions that resist demethylation in hPGCs also resist demethylation in the embryo's ICM, demonstrating that these loci are not fully erased during both waves of epigenetic reprogramming (Gkountela et al., 2015; Tang et al., 2015) .
New strategies to replicate hPGC formation in vitro
Scientists have tested different strategies in attempts to form artificial gametes from several cell types, with PSCs being used most frequently. Recent reviews have addressed this issue, and we will not duplicate these efforts (Hendriks et al., 2015; Moreno et al., 2015; Martínez-Arroyo et al., 2015; Vassena et al., 2015; Zeng et al., 2015) . Instead, we will focus on the recent work by Sasaki and colleagues; that work, to our knowledge, has made the most significant progress so far in the search for an in vitro differentiation strategy from pluripotent cells to PGCs (Sasaki et al., 2015) .
Human ESCs/iPSCs, while still capable of turning into a naïve state similar to mouse ESCs, are usually cultured as primed ESCs, reminiscent of mouse epiblast stem cells (EpiSCs) (Brons et al., 2007) . It is widely agreed that these cells resemble postgastrulation epiblasts and exhibit limited germ cell-differentiation capacity. Nonetheless, Saitou and colleagues, using mouse ESCs, found that the induction of pregastrulation epiblast-like cells from ESCs or iPSCs was an important step in the process of reprogramming pluripotent stem cells into PGC-like cells capable of producing offspring (Hayashi et al., 2011) . In recent work with human cells, the same group describes a new, more robust protocol that relies on differentiating hESCs into an incipient mesoderm-like cell state followed by induction of germ cells using known factors (BMP4, SCF, EGF and LIF). They established hiPSC lines using a TALEN-based strategy bearing reporters for BLIMP and TFAP2C (Sasaki et al., 2015) , two necessary and sufficient factors for mPGC specification expressed in human fetal germ cells (Eckert et al., 2008; Nakaki et al., 2013) . The group tracked differentiation efficiency by the expression of a gene reporter (BTAG-positive cells). They stimulated hiPSCs with activin A and a WNT-signaling agonist (CHIR99021), generating cells with a flat epithelial-like morphology that activated the expression of BTAG upon cytokine stimulation. These cells expressed genes for (naïve) pluripotency similar to hiPSCs and caused a modest upregulation of some mesoderm genes (EOMES, SP5, NKX1−2, WNT3, T, BMP4 and MIXL1), suggesting that they are incipient mesoderm cells. When compared to previously reported differentiation protocols, they observed a higher rate of cells expressing the gene reporter (40-60% versus 15-20%) and a decrease in cell death without significant differences in the gene expression profiles. In addition, these cells had similar transcription profiles to hPGCs isolated in vivo . This study suggests that, unlike in the mouse, hPGC specification involves activation and subsequent repression of the somatic mesodermal program. Human hESCs that express some mesoderm factors differentiated to a germ cell fate better than standard hESCs. This study also confirmed that BLIMP1 stabilizes germline transcription and represses neuronal differentiation. We will need additional in vivo studies to definitively confirm these findings.
Transdifferentiation or direct conversion
In addition to pluripotent stem cells, other cells-namely spermatogonia, mesenchymal stem cells, amniotic fluid, muscle and skin stem cells-have been tested for their potential to form germ cells, albeit with limited success (for references, see Zeng et al., 2015;  Table I ). However, encouraged by the success of transdifferentiation or direct conversion studies aiming toward other target cells, i.e. neurons, cardiomyocytes, blood progenitor cells or Sertolli cells (Ieda et al., 2010; Szabo et al., 2010; Vierbuchen et al., 2010; Pang et al., 2011; Tursun et al., 2011; Buganim et al., 2012) and by the recent work by Sasaki and colleagues (see above), which seems to provide credence to the notion that somatic cells could offer a valid source of PGCs, our laboratory has continued to pursue this direct conversion strategy for the generation of PGCs. The recent report by Medrano and colleagues, reporting that germline-related genes induced direct conversion of somatic cells into a germ cell-like phenotype in vitro, provides solid evidence that the goal is within reach (Medrano et al., 2016) .
Sequential steps to replicate hPGC specification by direct conversion A general strategy for direct conversion into different cell types involves the infection (or transfection) of a cocktail of transcription factors implicated in the differentiation of the desired cell type, followed by exposure to culture conditions that will favor the emergence of the target cells. The first clear example of transdifferentiating mouse somatic cells into neural cells initially screened 19 genes that are specifically expressed in neural tissues, that have important roles in neural development, or that were implicated in epigenetic reprogramming. Researchers introduced these genes into fibroblasts by viral infection followed by in vitro culture (Vierbuchen et al., 2010) . More recent studies have shown that a small number of factors, even just one or two factors, proved sufficient to convert numerous cell types, including human neurons (Chanda et al., 2014) . Small molecules have also proved capable of replacing the use of transgenes in mouse cells . Our laboratory, in contrast to previous strategies that flooded cells with several signaling molecules and genes to induce germ cells in vitro, has implemented a sequential hPGC induction strategy. We first inhibit of lineage-specific factors in the somatic cell and subsequently reactivate germ cell-related genes using specific master regulators and in vitro culture conditions that enable PGC differentiation.
We hypothesized that the overexpression of SOX17 and BLIMP1 might be crucial for repressing fibroblast-specific genes while blocking the default neuronal differentiation program triggered by cells that reach pluripotency. While BLIMP1 is not expressed in hESCs or human testes, we chose it because it is expressed in the Tcam2 human seminoma cell line, which is reportedly more closely related to isolated hPGCs than hPGC-LC in vivo . After overexpression of BLIMP1, we observed that the overexpression of BLIMP1 increased OCT4 and decreased P53 expression, inducing minor morphological changes, but when OCT4 was also overexpressed, the combination induced stark morphological changes. We have now incorporated SOX17 into our strategy to test whether this master regulator-alone or in combination with BLIMP1 and other factors related to pluripotency, such as OCT4, NANOG, etc.-can induce a germ cell state more efficiently.
Our findings support the hypothesis that the suppression of the default neural program occurs during the stepwise differentiation of human germ cells from hESCs (Sugawa et al., 2015) . In fact, we have frequently detected neural-like cells when inducing direct conversion towards germ cells using BLIMP1 and OCT4. SOX2, which is expressed in mPGCs but not in hPGCs, is a key factor during neural differentiation. In hESCs, BLIMP1 has been proposed as an upstream regulator that suppresses SOX2 while promoting germ cell specification . We are currently testing this differentiation mechanism experimentally in human somatic cells using a direct cell conversion model.
We are currently exploring the role of doublesex and mab-3-related transcription factor 1 (DMRT1), an evolutionarily conserved factor critical for male sex determination in vertebrates (Zarkower, 2013) . DMRT1 has been shown to have numerous interactions with relevant factors involved in pluripotency (UTF1 and MEIS1), epigenetic remodeling (DNMT1 and TRIM50), germ cell specification (STRA8, BMPR1A and RET) and other key cellular functions (TP53, IGF2R, HOXB4 and TRIM29); these interactions could play significant roles during PGC specification (Fig. 1) . DMRT1 prevents female reprogramming in the postnatal mammalian testis and is associated with testicular germ cell tumors (Kanetsky et al., 2011; Matson et al., 2011) . In the mouse, the DMRT1 protein is expressed in the genital ridge of both sexes and becomes male-specific at about E14.5, when testicular and ovarian differentiation becomes well established (Matson et al., 2010; Krentz et al., 2011) . Similarly in humans, DMRT1 is detected in PGCs and in the germ cells of male and female fetal gonads from Weeks 8 to 20, and it persists in male germ cells afterwards (Jørgensen et al., 2012; Pashai et al., 2012) .
Like other groups, we have detected DMRT1 during the early stages of germ cell differentiation in vivo at Week 8 and during in vitro differentiation (Jørgensen et al., 2012; Pashai et al., 2012) . DMRT1 binds and controls pluripotency via the transcriptional repression of ESRRB, NR5A2/ LRH1 and SOX2. In mice and humans, SOX2, along with other factors, binds to the DMRT1 promoter. DMRT1 is activated when SOX2 or OCT4 becomes depleted in ESCs, indirectly suggesting that SOX2, together with other pluripotent factors, could silence DMRT1 in pluripotent cells to maintain pluripotency (Loh et al., 2006; Sharov et al., 2008; Lister et al., 2009) . DMRT1 expression may indicate the cell's exit from a pluripotent state and the onset of fetal germ cell fate. In support of this hypothesis is the proven interaction, and concomitant expression, of DMRT1 and NANOS3, suggesting parallel functions for these two genes and reinforcing their putative role in fetal germ cell development (Krentz et al., 2013) . DMRT1 could also prove useful for identifying the early stages of PGC specification. It is one of the few factors expressed early in hPGC differentiation that is not expressed in hESCs or hiPSCs. It should be noted that DMRT1 is expressed in the human seminoma cell line Tcam2 and in the adult testis. Recapitulating the epigenetic reprogramming of PGCs is not a simple process. It entails the most dramatic DNA methylation erasure known, encompassing most of the genome, with the exception of some repetitive elements. The uncoupling of DNA methylation and transcription, a signature event during PGC specification, argues in favor of the activity of other repressive epigenetic marks, possibly including H3K9me3, which may participate in gene silencing. In hPGCs, BLIMP1 and SOX17 are considered important for the promotion of 5mC erasure, and the knockdown of BLIMP1 negatively affects the initiation of DNA demethylation , strongly suggesting that BLIMP1 could induce the epigenetic remodeling observed in PGCs and likely plays a key role during direct cell conversion.
Our preliminary results suggest that the expression of germ cellrelated factors can indeed reactivate germ cell specific genes. We overexpressed 20 germ cell-related factors (TFAP2C, PRDM14, DAZL, VASA, STELLA, NANOS3, BOLL, DAZ, EIF1AY, LARP7, NANOS2, NANOS3, OIT3, PPARG, PRDM15, PRMT5, PUMILIO, TBX3, TCEA3 and WT1) by viral infection in human fibroblasts. We used a pool of viruses containing five factors to infect cells, which we then cultured in different conditions, including in the presence of BMP-signaling compounds, retinoic acid, or small molecules. We then evaluated morphological changes and the expression of germ cell markers in fibroblasts after 1 month in culture. We detected the presence of round single cells that formed compact clumps and others that had a spindly morphology ( Fig. 2A) . Some of these cells maintained their expression of GFP, an indicator of ectopic transgene expression (Fig. 2B ). TNAP expression (Fig. 3A) and immunofluorescence analysis showed the endogenous expression of some human-specific germ cell markers, including SSEA1 and VASA (Fig. 3B) , suggesting that these cells could resemble an induced primordial germ cell-like (iPGCL) phenotype.
In addition, we have identified some positive interactions among germ cell-related genes, such as DAZL, STELLA and VASA, after observing the overexpression of these factors in somatic cells, i.e. human IMR90 fibroblasts (Fig. 4) . Overexpression of DAZL resulted in the upregulation of STELLA and VASA. STELLA overexpression also upregulated DAZL and VASA but not BOULE, another germ cellrelated factor. Similarly, the overexpression of VASA upregulated STELLA but not DAZL or BOLL.
Our preliminary results suggest that some germ cell-related factors can be reactivated in fibroblasts and, together with the recently reported use of specific factors and of reporter genes to track human germ cell development, could help us to get closer to our final aim, the clinical translational applications of germ cells.
Concluding remarks
Currently, we can obtain hiPSCs from different somatic cell types. However, the terminal differentiation of hESCs or hiPSCs remains imperfect; we must rely on in vivo differentiation conditions to obtain mature, functional cells. It seems too early to assume that we can generate gametes, such as swimming spermatozoa or oocytes, from a culture of somatic cells in a dish. Generating PGCs is a more attainable goal that brings us closer to making functional gametes.
Given the fundamental role of PGCs in perpetuating the species and transmitting genetic and epigenetic information to the next generation, a complete understanding of the PGC specification process promises to provide considerable benefits for the treatment of patients with deficient or aberrant gamete formation (Pacheco et al., 2011; Heyn et al., 2012; Ferreira et al., 2014) .
Direct conversion, another promising strategy, could take cells that have already initiated the expression of a somatic program into the PGC specification process in vitro. Preliminary evidence from our group demonstrates that we can induce fibroblasts to express early PGC markers and morphological changes resembling germ cells. However, it would be premature to state that gametes are forthcoming. Still, further explorations of the differentiation approaches described here will undoubtedly increase our knowledge of fundamental processes, such as germ cell specification, epigenetic remodeling, cell-fate conversion and transgenerational inheritance.
